Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Up 23.7% in September

Compass Therapeutics, Inc. (NASDAQ:CMPX) was the target of a large increase in short interest in the month of September. As of September 15th, there was short interest totalling 2,300,000 shares, an increase of 23.7% from the August 31st total of 1,860,000 shares. Currently, 2.7% of the company’s shares are sold short. Based on an average daily trading volume, of 437,600 shares, the short-interest ratio is presently 5.3 days.

Compass Therapeutics Trading Up 3.9 %

CMPX opened at $1.88 on Monday. The company has a market cap of $258.67 million, a P/E ratio of -5.22 and a beta of 0.88. The company has a fifty day moving average price of $1.33 and a two-hundred day moving average price of $1.41. Compass Therapeutics has a 1-year low of $0.77 and a 1-year high of $2.34.

Compass Therapeutics (NASDAQ:CMPX) last issued its earnings results on Monday, August 12th. The company reported ($0.10) EPS for the quarter, meeting analysts’ consensus estimates of ($0.10). The firm had revenue of $0.85 million during the quarter. On average, research analysts forecast that Compass Therapeutics will post -0.42 EPS for the current fiscal year.

Institutional Investors Weigh In On Compass Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Pale Fire Capital SE lifted its holdings in shares of Compass Therapeutics by 301.0% in the 4th quarter. Pale Fire Capital SE now owns 181,055 shares of the company’s stock worth $282,000 after purchasing an additional 135,900 shares in the last quarter. Pennant Investors LP acquired a new position in Compass Therapeutics during the fourth quarter worth $310,000. Bleakley Financial Group LLC bought a new position in shares of Compass Therapeutics in the first quarter valued at $80,000. Vanguard Group Inc. lifted its holdings in shares of Compass Therapeutics by 1.7% in the first quarter. Vanguard Group Inc. now owns 4,152,197 shares of the company’s stock valued at $8,221,000 after purchasing an additional 71,008 shares in the last quarter. Finally, CM Management LLC lifted its stake in Compass Therapeutics by 148.0% during the 1st quarter. CM Management LLC now owns 310,000 shares of the company’s stock valued at $614,000 after acquiring an additional 185,000 shares in the last quarter. Institutional investors own 68.43% of the company’s stock.

Analyst Upgrades and Downgrades

CMPX has been the subject of several recent research reports. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a research report on Monday, August 12th. LADENBURG THALM/SH SH upgraded Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price objective for the company in a report on Monday, September 16th. Finally, Wedbush reaffirmed an “outperform” rating and set a $8.00 target price on shares of Compass Therapeutics in a report on Wednesday, August 7th.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.